Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1586/14737140.2016.1143779 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Thyroid cancer.
Med Clin (Barc)
January 2025
Servicio de Endocrinología y Nutrición, Hospital i Institut de Recerca Germans Trias i Pujol, Universitat Autònoma de Barcelona, España. Electronic address:
In recent decades, the diagnosis of thyroid cancer, especially the papillary type, has increased significantly due to the use of imaging techniques such as ultrasound. For this reason, it is essential to rationalize diagnosis and treatment, since the behavior of thyroid cancer varies from slow-progressing tumors to highly aggressive ones. The application of risk assessment systems for ultrasound images and the optimization of cytology incorporating molecular studies allows cases to be stratified in order to select therapy on an individual basis.
View Article and Find Full Text PDFNeoadjuvant chemotherapy in locally advanced colon cancer: A systematic review with proportional meta-analysis.
Eur J Surg Oncol
December 2024
Department of Medical Oncology, Catharina Hospital, Eindhoven, Netherlands.
Neoadjuvant chemotherapy is suggested in locally advanced colon cancer. Data on improved long-term oncological outcomes are lacking, which hampers the implementation in clinical practice. This systematic review provides an overview of the benefits and drawbacks of neoadjuvant chemotherapy in patients with locally advanced colon cancer.
View Article and Find Full Text PDFPituitary adenomas: biology, nomenclature and clinical classification.
Rev Endocr Metab Disord
January 2025
Pituitary Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
An 'adenoma' is a benign neoplasm composed of epithelial tissue, and has been standard nomenclature for primary pituitary neoplasms. In 2022, the fifth edition of the WHO Classification of Endocrine Tumours and of Central Nervous System Tumours, renamed pituitary adenomas as neuroendocrine tumours (NETs), assigning an oncology label to pituitary invariably benign neoplasms. Multidisciplinary workshops convened by the Pituitary Society have questioned the process, validity, and merit of this arbitrary change, while addressing the adverse clinical implications of the proposed new nomenclature.
View Article and Find Full Text PDFCIRCULATING miR-1-3p, miR-96-5p, miR-148a-3p, and miR-375-3p Support Differentiation Between Prostate Cancer and Benign Prostate Lesions.
Clin Genitourin Cancer
December 2024
Department of Urology, Centre of Postgraduate Medical Education, Independent Public Hospital of Prof. W. Orlowski, Warsaw, Poland.
Introduction: microRNAs (miRNAs) are small noncoding RNAs and promising cancer biomarkers. Prostate-specific antigen (PSA) testing revolutionized prostate cancer (PCa) diagnostics and monitoring. However, PSA testing also contributes to PCa overdiagnoses that are detrimental on patients' health and may lead to overtreatment.
View Article and Find Full Text PDFA systematic review of outcomes reported in studies to optimise the medication use of patients at hospital discharge.
BMC Health Serv Res
January 2025
Department Pharmaceutical Sciences, University of Basel, Basel, Switzerland.
Introduction: Care transitions, specifically hospital discharge, hold a risk for drug-related problems and medication errors. Effective interventions that optimise medication use during and after transitions are needed, yet there is no standardisation of the outcomes. This literature review aimed at collecting outcomes from studies investigating how to optimise medication use of patients following hospital discharge, and to categorise them, as a first step in the development of a core outcome set.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!